1300: Efficacy and safety of BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M-positive NSCLC at the recommended phase II dose. Park K,Lee J-S,Han J-Y, Lee K H,Kim J-H, Cho E K, Cho J Y,Min Y J, Kim J-S,Kim D-WJOURNAL OF THORACIC ONCOLOGY（2016）引用 34|浏览2暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
